BOUTIQUE intellectual property firm, Pearce IP, which specialises in the pharmaceutical and biopharmaceuticals sectors, has now joined the Generic and Biosimilar Medicines Association (GBMA).
GBMA's Chief Executive Officer Marnie Peterson said Pearce IP has joined as its newest Associate Member, as the sector "undergoes significant reform, including implementation of the GBMA's five-year Strategic Agreement with the Government".
GBMA's Independent Chair, Prof Jane Halton welcomed Pearce IP to the shared mission of ensuring all Australian patients had secured access to safe and affordable medicines, in particular biosimilars.
"More needed to be done to unlock the health and fiscal benefits of biosimilars to deliver savings and restore balance to an over-stretched health budget," Halton said.
Founder and Chief Executive Officer of Pearce IP, Naomi Pearce, agreed saying she was committed to supporting the GBMA as it developed policies that further enabled all Australians to access these affordable medicines.
"Throughout the last few years, companies supplying medicines have been challenged and stretched in ways that no one could have foreseen," explained Pearce.
"Having collaborated with GBMA members for more than two decades, I am proud that Pearce IP is strengthening our support for this sector and the patients it serves, in these challenging times."
Peterson said that drawing on the insights of members, such as Pearce IP, the GBMA would continue to advocate for medicine access policies that supported healthcare sustainability for the long term.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Jun 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Jun 23
